New York, New York 10029


Purpose:

Use of co-induction with corticosteroid therapies may accelerate the remission rate when used with vedolizumab. Further, this may lead to higher rates of response and remission at week 10 than would be seen with vedolizumab monotherapy.


Study summary:

This study will examine prednisone co-induction with vedolizumab in patients with Crohn's disease. To address questions regarding the effect of co-induction on mucosal healing, the study will include colonoscopic assessment of mucosal healing. Finally, colonic biopsies in this study will allow to elucidate further the mechanism of action of vedolizumab in Crohn's disease through immune phenotyping studies.


Criteria:

Inclusion Criteria: - Age at entry 18 to 70 - CDAI score > 220 - Concomitant azathioprine, methotrexate, or mercaptopurine permitted if dose has been stable for > 8 weeks. Prior anti-TNFα antibody use permitted but must be discontinued (>2 weeks from last dose) prior to initiation of vedolizumab. - Documented ulceration on colonoscopy done at screening of 3 or more large ulcers or 10 or more aphthous ulcers - Able to provide written informed consent. - Patient is planned for or eligible to initiate vedolizumab Exclusion Criteria: - Concurrent use of anti-TNFα antibodies. - No corticosteroids within prior 3 months (other than budesonide controlled ileal release) - No stoma at the time of enrollment - No absolute contraindication to systemic corticosteroid use such as hypersensitivity to any part of the formulation, systemic fungal infection, or recent administration of live or live attenuated vaccine within prior two weeks. - Pregnant women or plans for pregnancy within 3 months of study inclusion - Presence of stoma, more than three small-bowel resections, or documented history of short bowel syndrome - Intestinal stricture requiring surgery - Abdominal abscess - Inability or unwillingness to provide informed consent - Any other condition, which, in the opinion of the investigators would impede competence or compliance or possibly hinder completion of the study


NCT ID:

NCT02324699


Primary Contact:

Principal Investigator
Bruce E Sands, MD, MS
Icahn School of Medicine at Mount Sinai Hospital

Neeraj Narula
Phone: 212-241-2230
Email: neeraj.narula@medportal.ca


Backup Contact:

N/A


Location Contact:

New York, New York 10029
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.